Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial-Reference-Cited by-同舟云学术

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Published:2012-03 Issue:3 Volume:13 Page:247-255
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Paz-Ares Luis,de Marinis Filippo,Dediu Mircea,Thomas Michael,Pujol Jean-Louis,Bidoli Paolo,Molinier Olivier,Sahoo Tarini Prasad,Laack Eckart,Reck Martin,Corral Jesús,Melemed Symantha,John William,Chouaki Nadia,Zimmermann Annamaria H,Visseren-Grul Carla,Gridelli Cesare

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Surgical treatment of locally advanced non-small cell lung cancer;Swisher,2002

2. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;D'Addario;Ann Oncol,2010

3. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer;Azzoli;J Clin Oncol,2009

4. Optimizing first-line treatment options for patients with advanced NSCLC;Wakelee;Oncologist,2005

5. Bevacizumab in non small cell lung cancer;Sandler;Clin Cancer Res,2007

Cited by 510 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non–small cell lung cancer and mutated EGFR;Supportive Care in Cancer;2023-12-27

2. Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial;British Journal of Cancer;2023-12-14

3. Treatment Patterns and Adverse Event-Related Hospitalization Among Patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-small Cell Lung Cancer After Treatment with EGFR Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy Regimens;Drugs - Real World Outcomes;2023-09-02

4. First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis;Translational Lung Cancer Research;2023-09

5. Immune Checkpoint Inhibitor without Pemetrexed for First-line Maintenance Therapy in Advanced Lung Adenocarcinoma: A real-world retrospective study;2023-08-25